Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

PURPOSE: Based on promising predinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2(mut) nonamplified metastatic breast cancer (MBC). Secondary endpoints i...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Ma, Cynthia X., Bose, Ron, Gao, Feng, Freedman, Rachel A., Telli, Melinda L., Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P., Russell, Christy, Tripathy, Debu, Cobleigh, Melody, Forero, Andres, Pluard, Timothy J., Anders, Carey, Niravath, Polly Ann, Thomas, Shana, Anderson, Jill, Bumb, Caroline, Banks, Kimberly C., Lanman, Richard B., Bryce, Richard, Lalani, Alshad S., Pfeifer, John, Hayes, Daniel F., Pegram, Mark, Blackwell, Kimberly, Bedard, Philippe L., Al-Kateb, Hussam, Ellis, Matthew J.C.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6746403/
https://ncbi.nlm.nih.gov/pubmed/28679771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0900
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker